Bastian Dehmel
Corporate Officer/Principal at OCULIS HOLDING AG
Profile
Bastian Dehmel is currently the Chief Development Officer at Oculis Holding AG.
Previously, he held the position of Executive Director-Global Medical Development at Amgen (Europe) GmbH from 2013 to 2017 and Chief Medical Officer at OxThera AB from 2017 to 2021.
Dr. Dehmel obtained a doctorate degree from Freie Universität Berlin.
Bastian Dehmel active positions
| Companies | Position | Start |
|---|---|---|
| OCULIS HOLDING AG | Corporate Officer/Principal | 31/12/2021 |
Former positions of Bastian Dehmel
| Companies | Position | End |
|---|---|---|
OxThera AB
 OxThera AB Pharmaceuticals: GenericHealth Technology OxThera AB develops pharmaceutical products for treatment of hyperoxaluria. Its intellectual property includes worldwide patents for compositions and treatment of hyperoxaluria with bacteria and enzymes. The firm?s products in pipeline include Oxabact, for the treatment of primary hyperoxaluria and oxazyme for the prevention of oxalate malabsorption and recurring kidney stones in secondary hyperoxaluria. The company was founded in 2005 and is headquartered in Stockholm, Sweden. | Chief Tech/Sci/R&D Officer | 30/11/2021 |
| Amgen (Europe) GmbH | Corporate Officer/Principal | 30/06/2017 |
Training of Bastian Dehmel
| Freie Universität Berlin | Doctorate Degree |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Listed companies | 1 |
|---|---|
| OCULIS HOLDING AG | Health Technology |
| Private companies | 2 |
|---|---|
OxThera AB
OxThera AB Pharmaceuticals: GenericHealth Technology OxThera AB develops pharmaceutical products for treatment of hyperoxaluria. Its intellectual property includes worldwide patents for compositions and treatment of hyperoxaluria with bacteria and enzymes. The firm?s products in pipeline include Oxabact, for the treatment of primary hyperoxaluria and oxazyme for the prevention of oxalate malabsorption and recurring kidney stones in secondary hyperoxaluria. The company was founded in 2005 and is headquartered in Stockholm, Sweden. | Health Technology |
| Amgen (Europe) GmbH |
- Stock Market
- Insiders
- Bastian Dehmel
